ANZCTR search results

The purpose of this project is to investigate changeover from a person's current antipsychotic drug to a relatively new drug for the treatment of schizophrenia. This drug, Aripiprazole, works differently than any other antipsychotic drugs that have been previously available. Therefore, this study is important because the current knowledge is limited and it will allow a better understanding of a safe and effective way to switch over.

Thirty participants were assigned to either CBT, SE PDT or EFT group therapy for 9 weeks, while 28 participants were assigned to either CBT, or SE PDT for 14 weeks. The results showed that group therapy over both 9 weeks and 14 weeks significantly reduced anxiety and depressive symptom with gains maintained at 6-month follow-up. No significant differences were found between dosages or therapies at post-therapy. However, at 6-month follow-up, group CBT benefited recovery by 15% compared with group SE PDT.

INTERACT is an academic, international clinical trial to establish the possibility of undertaking a large scale study in 6,000 patients with acute intracerebral haemorrhage (bleeding into the brain) within 6 hours of onset and who also have associated high blood pressure. 400 patients will be recruited from Australia, New Zealand, China, Singapore and the United States of America. Patients will be assigned to either intensive blood pressure lowering treatment or current guideline based management of blood pressure alongside routine stroke management. Participants will be visited for 7 days during their hospital stay and then followed up at 1 month and 3 months intervals. The majority of information will be collected using standardised questionnaires and stroke scales. The study is a trial of blood pressure lowering policy using approved drugs within their labelling restrictions. The main purpose of the studyis to review the numbers of deaths and number of patients permanenetly disabled at 3 months.

For further information, please see www.clinicaltrials.gov NCT00066573

Breast cancer sometimes recurs locally (comes back in the breast, chest or lymph nodes) despite the best initial treatment. Women with breast cancer that has recurred locally are usually treated with further surgery, radiation and/or hormone therapy. This international phase III trial will determine if adding chemotherapy to the standard treatment for a local recurrence can further improve cure rates for such women. Women who enter the trial will be randomly assigned to receive standard treatment or standard treatment plus chemotherapy. The type of chemotherapy will be chosen by the treating doctor.